TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure Ketamine’s psychedelic effect on cerebral cortex hemodynamics. On January 11, 2021 Cybin announced that it would be partnering with…


Previous articleSmall Pharma Inc. Expands Phase I/IIa Clinical Trial With Additional Study Site
Next articlePsychedelics and Cannabis ETF Launches on NYSE Arca in First for the U.S.